SCHEMBL6364898

SCHEMBL6364898

CCC(CC)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
CASP3 P42574 1/20 0.47
LMNA P02545 1/20 0.46
ALDH1A1 P00352 6/20 0.44
GAA P10253 2/20 0.44
GALR3 O60755 1/20 0.44
POLB P06746 2/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
NFKB1 P19838 1/20 0.43
APEX1 P27695 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
DRD3 P35462 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15241103 0.88 TDP1 (0.46) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL15240556 0.88 TDP1 (0.46) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL7054656 0.88 TDP1 (0.46) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL14479254 0.85 TDP1 (0.44) TDP1CASP3LMNAALDH1A1POLB
SCHEMBL19285617 0.84 CASP3 (0.46) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL11685677 0.84 TNF (0.52) TDP1LMNAALDH1A1GAAPOLB
SCHEMBL19285667 0.84 CASP3 (0.46) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL19285619 0.84 CASP3 (0.46) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL18909733 0.83 TDP1 (0.49) TDP1CASP3LMNAALDH1A1GAA
SCHEMBL12382279 0.83 TERT (0.41) TDP1LMNAALDH1A1GALR3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321124-A1 ROR gamma t Inhibitors and Topical Uses Thereof DERMIRA, INC. 2023-10-12 US disclosed
US-20230260787-A1 COMPOSITION FOR FORMING PROTECTIVE FILM AGAINST ALKALINE AQUEOUS HYDROGEN PEROXIDE, SUBSTRATE FOR PRODUCING SEMICONDUCTOR APPARATUS, METHOD FOR FORMING PROTECTIVE FILM, AND METHOD FOR FORMING PATTERN SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-08-17 US disclosed
WO-2021106627-A1 POLYIMIDE, POLYIMIDE RESIN FILM, MULTILAYER BODY AND FLEXIBLE DEVICE 東レ株式会社 2021-06-03 WO disclosed
US-20200172731-A1 BINDER RESIN FOR ELECTRODES, ELECTRODE MIXTURE PASTE, ELECTRODE AND METHOD FOR PRODUCING ELECTRODE UBE CORPORATION (JP) 2020-06-04 US disclosed
US-9834520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-05 US disclosed
WO-2012068439-A1 OPTICAL ARTICLE WITH LENS COMPRISING POLYIMIDE SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2012-05-24 WO disclosed
US-6858070-B1 Phase change inks XEROX CORPORATION (US) 2005-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321124-A1 ROR gamma t Inhibitors and Topical Uses Thereof RORC, RORB, RORA TDP1 3589/4885CASP3 4586/4885LMNA 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.